Loading…
GT Biopharma, Inc. is projected to decline to $0.2486 by 2027, a -19% move from its current price of $0.3086. GTBP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.2949 | $0.3084 | $0.3226 | -0.06% |
| Aug 6 | $0.2892 | $0.3082 | $0.3284 | -0.13% |
| Aug 7 | $0.285 | $0.308 | $0.3329 | -0.19% |
| Aug 8 | $0.2814 | $0.3078 | $0.3368 | -0.25% |
| Aug 9 | $0.2782 | $0.3076 | $0.3401 | -0.32% |
| Aug 10 | $0.2754 | $0.3074 | $0.3432 | -0.38% |
| Aug 11 | $0.2728 | $0.3072 | $0.346 | -0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2728 | $0.3072 | $0.346 | -0.44% |
| Week 2 | $0.2585 | $0.3059 | $0.3619 | -0.88% |
| Week 3 | $0.2479 | $0.3045 | $0.3741 | -1.32% |
| Week 4 | $0.239 | $0.3032 | $0.3845 | -1.76% |
| Week 5 | $0.2314 | $0.3018 | $0.3937 | -2.19% |
| Week 6 | $0.2246 | $0.3005 | $0.4021 | -2.63% |
| Week 7 | $0.2184 | $0.2992 | $0.4097 | -3.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company that engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
GT Biopharma, Inc. (GTBP) is a healthcare company whose stock is currently trading at $0.2935. The asset sits in the public markets with a market capitalization of $10.58M and a rank of 5070.
A major floor 52.3% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 66.6% above — a clean break opens room to run.
A major ceiling 90.3% above — clearing it would confirm fresh momentum.
Key GTBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GTBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.311 | Sell | $0.3094 | Sell |
| MA 10 | $0.3259 | Sell | $0.3272 | Sell |
| MA 20 | $0.3698 | Sell | $0.3576 | Sell |
| MA 50 | $0.4174 | Sell | $0.3942 | Sell |
| MA 100 | $0.4046 | Sell | $0.4443 | Sell |
| MA 200 | $0.5281 | Sell | $0.6815 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.58 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -106.75 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -16.00 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.01 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 23.84 | Buy |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.30 | Buy |
| ADX (14) | 20.42 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 30. Key moving averages are $0.4174 (SMA50) and $0.5281 (SMA200). Near-term support is $0.294 and resistance is $0.514. The 30-day price range runs from $0.2183 to $0.3947, and annualized volatility stands at 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.272 | $0.3086 | $0.3789 | 0% | Neutral | |
| $0.1867 | $0.2486 | $0.356 | -19% | Bearish | |
| $0.193 | $0.2701 | $0.4094 | -12% | Neutral | |
| $0.2328 | $0.3399 | $0.538 | +10% | Neutral | |
| $0.2233 | $0.3385 | $0.5555 | +10% | Neutral | |
| $0.2396 | $0.3762 | $0.6367 | +22% | Bullish | |
| $0.2332 | $0.3783 | $0.6582 | +23% | Bullish | |
| $0.1851 | $0.3098 | $0.5526 | 0% | Neutral | |
| $0.1919 | $0.3311 | $0.604 | +7% | Neutral | |
| $0.199 | $0.3537 | $0.6587 | +15% | Neutral | |
| $0.2348 | $0.4795 | $0.973 | +55% | Bullish | |
| $0.4366 | $0.9703 | $2.22 | +214% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.272 | $0.3086 | $0.3877 | +0.00% |
| September 2026 | $0.2505 | $0.3018 | $0.3775 | -2.22% |
| October 2026 | $0.239 | $0.2913 | $0.3707 | -3.48% |
| November 2026 | $0.2421 | $0.2978 | $0.3844 | +2.25% |
| December 2026 | $0.2337 | $0.29 | $0.3789 | -2.63% |
Click any year to see its month-by-month GTBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GTBP price prediction for 2026 points to an average of $0.3086 (low $0.272, high $0.3789) — a potential gain of 0% on today's $0.3086. Price action looks broadly range-bound.
In 2027, GTBP is projected to trade between $0.1867 and $0.356, averaging $0.2486 — a potential decline of -19% from today's $0.3086. That is -19% versus the projected 2026 average. Expect choppier, lower action through this leg of the cycle.
GT Biopharma, Inc.'s 2028 outlook centres on $0.2701, within a $0.193 to $0.4094 range. That is up +9% on the projected 2027 average. That marks a -12% change versus current levels. Price action looks broadly range-bound.
By 2029, GTBP could reach as high as $0.538, with a base case around $0.3399 and support toward $0.2328 — roughly +10% from $0.3086. A consolidation phase looks the most probable path here.
Expect GTBP to range from $0.2233 to $0.5555 through 2030. The $0.3385 average target implies a +10% move from current prices. That is 0% versus the projected 2029 average. Price action looks broadly range-bound.
The GTBP price prediction for 2031 points to an average of $0.3762 (low $0.2396, high $0.6367) — a potential gain of +22% on today's $0.3086. Buyers look set to stay in control over this stretch.
In 2032, GTBP is projected to trade between $0.2332 and $0.6582, averaging $0.3783 — a potential gain of +23% from today's $0.3086. That is up +1% on the projected 2031 average. Momentum favours further upside here.
GT Biopharma, Inc.'s 2033 outlook centres on $0.3098, within a $0.1851 to $0.5526 range. That is -18% versus the projected 2032 average. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, GTBP could reach as high as $0.604, with a base case around $0.3311 and support toward $0.1919 — roughly +7% from $0.3086. Price action looks broadly range-bound.
Expect GTBP to range from $0.199 to $0.6587 through 2035. The $0.3537 average target implies a +15% move from current prices. That is up +7% on the projected 2034 average. A consolidation phase looks the most probable path here.
The GTBP price prediction for 2040 points to an average of $0.4795 (low $0.2348, high $0.973) — a potential gain of +55% on today's $0.3086. Momentum favours further upside here.
In 2050, GTBP is projected to trade between $0.4366 and $2.22, averaging $0.9703 — a potential gain of +214% from today's $0.3086. That is up +102% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GTBP today (≈ 3,240.4407 GTBP) could be worth
$3,144.2
+$2,144.2 (+214%) by 2050 · US Dollar
Based on the average projected GTBP price of $0.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GTBPwould be worth at today's price.
$1,000 invested in GTBP on Jul 31, 2025 (≈ 537.634404 GTBP) would be worth
$165.91
-$834.09 (-83.4%) today · 0.17× · US Dollar
Based on a GTBP entry price of $1.86 vs. today's $0.3086.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.324 | $952.47 | -4.8% |
| 1 month ago | $0.494 | $624.7 | -37.5% |
| 3 months ago | $0.343 | $899.71 | -10.0% |
| 6 months ago | $0.51 | $605.1 | -39.5% |
| 1 year ago | $1.86 | $165.91 | -83.4% |
| All time (5.0y) ago | $339 | $0.91 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GTBP forecast.
Our base-case forecast reaches $0.62 around 2050.
Implied market cap at $0.62: $22.36M
The multi-year forecast shows a path of evolving sentiment and price levels. For 2026 the avg price is $0.2935 with a min of $0.272 and a max of $0.3597, and ROI of 0% (sentiment NEUTRAL). The forecast then dips in 2027 to a min of $0.1777 and avg $0.2366 (max $0.3389) with an ROI of -19.4% (BEARISH), followed by a recovery in 2028 (avg $0.2574; max $0.3901; ROI -12.3%).
In 2029 the avg is $0.3229 with a max of $0.5111 and ROI of 10% (NEUTRAL), and in 2030 the avg is $0.3221 with a max of $0.5286 and ROI of 9.8% (NEUTRAL). The outlook becomes more bullish in 2031 (avg $0.3584; max $0.6067; ROI 22.1%), and 2032 (avg $0.3595; max $0.6255; ROI 22.5%). 2033 shows a neutral stance (avg $0.2945; max $0.5252; ROI 0.3%), followed by 2034 (avg $0.3154; max $0.5753; ROI 7.5%) and 2035 (avg $0.3365; max $0.6266; ROI 14.6%).
The long arc turns decisively bullish by 2040 (avg $0.4571; max $0.9276; ROI 55.7%) and remains strongly bullish through 2050 (avg $0.9219; max $2.11; ROI 214.1%).
Tap a question to reveal the answer.
Avg $0.3221; min $0.2125; max $0.5286; ROI 9.8%; sentiment NEUTRAL.
Near term shows mixed signals (2026 NEUTRAL; 2027 BEARISH; 2028 NEUTRAL; 2029 NEUTRAL; 2030 NEUTRAL). Longer term indicates bullish potential in 2031 and 2032 (ROI 22.1% and 22.5%), with substantial upside by 2040 (ROI 55.7%) and 2050 (ROI 214.1%).
Yes. The forecast max is $2.11 in 2050 (avg $0.9219; min $0.4149; ROI 214.1%).
Current price $0.2935; Market Cap $10.58M.
RSI14 is 30 with BEARISH sentiment. SMA50 is $0.4174 and SMA200 is $0.5281. Support is $0.294 and resistance is $0.514. The 30-day range is $0.2183 to $0.3947, with annualized volatility of 90%.
GT Biopharma, Inc. Community Discussion
0Share your GT Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.